- Home
- FLYE vs EQ Comparison
FLYE vs EQ Comparison
Compare FLYE & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLYE
- EQ
- Stock Information
- Founded
- FLYE 2018
- EQ 2017
- Country
- FLYE United States
- EQ United States
- Employees
- FLYE N/A
- EQ N/A
- Industry
- FLYE Aerospace
- EQ Biotechnology: Pharmaceutical Preparations
- Sector
- FLYE Industrials
- EQ Health Care
- Exchange
- FLYE Nasdaq
- EQ Nasdaq
- Market Cap
- FLYE 10.2M
- EQ 12.2M
- IPO Year
- FLYE 2024
- EQ 2018
- Fundamental
- Price
- FLYE $5.61
- EQ $0.42
- Analyst Decision
- FLYE
- EQ Buy
- Analyst Count
- FLYE 0
- EQ 3
- Target Price
- FLYE N/A
- EQ $3.00
- AVG Volume (30 Days)
- FLYE 818.5K
- EQ 544.3K
- Earning Date
- FLYE 08-18-2025
- EQ 08-07-2025
- Dividend Yield
- FLYE N/A
- EQ N/A
- EPS Growth
- FLYE N/A
- EQ N/A
- EPS
- FLYE N/A
- EQ N/A
- Revenue
- FLYE $25,427,163.00
- EQ $30,406,000.00
- Revenue This Year
- FLYE N/A
- EQ N/A
- Revenue Next Year
- FLYE N/A
- EQ N/A
- P/E Ratio
- FLYE N/A
- EQ N/A
- Revenue Growth
- FLYE N/A
- EQ N/A
- 52 Week Low
- FLYE $1.65
- EQ $0.27
- 52 Week High
- FLYE $33.60
- EQ $1.50
- Technical
- Relative Strength Index (RSI)
- FLYE N/A
- EQ 63.74
- Support Level
- FLYE N/A
- EQ $0.29
- Resistance Level
- FLYE N/A
- EQ $0.45
- Average True Range (ATR)
- FLYE 0.00
- EQ 0.05
- MACD
- FLYE 0.00
- EQ 0.01
- Stochastic Oscillator
- FLYE 0.00
- EQ 65.84
About FLYE Fly-E Group Inc. Common Stock
Fly-E Group Inc is an electric vehicle company that is principally engaged in designing, installing and selling smart electric motorcycles, electric bikes, electric scooters and related accessories under the brand Fly E-Bike. It also provides connectivity solutions and value-added services to their customers.
About EQ Equillium Inc.
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.